{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:16:18Z","timestamp":1791998178385,"version":"4.4.0"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023SK4052"],"award-info":[{"award-number":["2023SK4052"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009020","name":"University of South China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009020","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bbrc.2025.152826","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T19:46:53Z","timestamp":1760730413000},"page":"152826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Applications and challenges of EGFR inhibitors in the treatment of nasopharyngeal carcinoma"],"prefix":"10.1016","volume":"788","author":[{"given":"Qinglin","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4794-4637","authenticated-orcid":false,"given":"Ailan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbrc.2025.152826_bib1","first-page":"229","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.bbrc.2025.152826_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.29670","article-title":"Cancer incidence in five continents: inclusion criteria, highlights from volume x and the global status of cancer registration","volume":"137","author":"Bray","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2025.152826_bib3","doi-asserted-by":"crossref","unstructured":"C. Tang, R. Lan, D.-R. Ma, et al., Annexin a1: the dawn of ischemic stroke (review), Mol. Med. Rep. 31(3) 62.https:\/\/doi.org\/10.3892\/mmr.2024.13427.","DOI":"10.3892\/mmr.2024.13427"},{"key":"10.1016\/j.bbrc.2025.152826_bib4","doi-asserted-by":"crossref","unstructured":"P. Blanchard, J. Biau, F. Huguet, et al., Radiotherapy for nasopharyngeal cancer, Cancer Radiother. : J. de la Societe francaise de radiotherapi e oncologique 26(1\u20132) 168-173.https:\/\/doi.org\/10.1016\/j.canrad.2021.08.009.","DOI":"10.1016\/j.canrad.2021.08.009"},{"key":"10.1016\/j.bbrc.2025.152826_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.oraloncology.2015.11.015","article-title":"Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma","volume":"53","author":"Setton","year":"2016","journal-title":"Oral Oncol."},{"key":"10.1016\/j.bbrc.2025.152826_bib6","doi-asserted-by":"crossref","unstructured":"Y. Tian, W.-Z. Huang, L. Zeng, et al., The failure patterns of nasopharygeal carcinoma after intensity-modula ted radiotherapy and implications for surveillance, Cancer Manag. Res. 14 2813-2823.https:\/\/doi.org\/10.2147\/CMAR.S347864.","DOI":"10.2147\/CMAR.S347864"},{"issue":"9","key":"10.1016\/j.bbrc.2025.152826_bib7","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/cncr.25754","article-title":"Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: Long-term results of a phase 2 study","volume":"117","author":"Xiao","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bbrc.2025.152826_bib8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41392-020-00340-2","article-title":"Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma","volume":"5","author":"Kang","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"12","key":"10.1016\/j.bbrc.2025.152826_bib9","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1007\/s00405-023-08157-9","volume":"280","author":"Luo","year":"2023","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"10.1016\/j.bbrc.2025.152826_bib10","doi-asserted-by":"crossref","unstructured":"L. Chen, L. Sun, L. Dong, et al., The role of long noncoding rna-let in cell proliferation and invasion of nasopharyngeal carcinoma and its mechanism, OncoTargets Ther. 10 2769-2778.https:\/\/doi.org\/10.2147\/OTT.S126907.","DOI":"10.2147\/OTT.S126907"},{"issue":"18_suppl","key":"10.1016\/j.bbrc.2025.152826_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.16510","article-title":"Evaluation of epidermal growth factor receptor (egfr) in nasopharyngeal carcinoma and lymph node metastases: implications for egfr targeted therapy","volume":"25","author":"Huang","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2025.152826_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2025.110001","article-title":"The coevolutionary landscape of drug resistance in epidermal growth factor receptor: a cancer perspective","volume":"189","author":"Rai","year":"2025","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.bbrc.2025.152826_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110649","article-title":"Anti-egfr therapies in nasopharyngeal carcinoma","volume":"131","author":"Chen","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2025.152826_bib14","unstructured":"L. Raimondi, L. Rossi, G. Cimino, et al., Astonishing response to cetuximab in metastatic nasopharyn- geal carci noma: a case report, La Clinica terapeutica 172(4) 260-263.https:\/\/doi.org\/10.7417\/CT.2021.2327."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152826_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/lio2.1279","article-title":"The efficacy and safety of egfr-tki in recurrent\/metastatic nasopharyngeal carcinoma patients: a systematic review and meta-analysis","volume":"9","author":"An","year":"2024","journal-title":"Laryngoscope Investigative Otolaryngol."},{"issue":"2","key":"10.1016\/j.bbrc.2025.152826_bib16","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijrobp.2017.09.038","article-title":"Facility volume and survival in nasopharyngeal carcinoma","volume":"100","author":"Yoshida","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152826_bib17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0360-3016(96)00416-6","article-title":"The role of brachytherapy in early-stage nasopharyngeal carcinoma","volume":"36","author":"Chang","year":"1996","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152826_bib18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.radonc.2012.08.001","article-title":"The battle against nasopharyngeal cancer","volume":"104","author":"Lee","year":"2012","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.bbrc.2025.152826_bib19","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.2147\/CMAR.S341472","article-title":"Advanced nasopharyngeal carcinoma: current and emerging treatment options","volume":"14","author":"Jiromaru","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bbrc.2025.152826_bib20","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/j.canrad.2016.07.031","article-title":"Radioth\u00e9rapie des cancers du nasopharynx","volume":"20","author":"Maingon","year":"2016","journal-title":"Cancer Radiother."},{"issue":"23","key":"10.1016\/j.bbrc.2025.152826_bib21","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1200\/JCO.2016.68.2476","article-title":"The sound of silence: a proxy for platinum toxicity","volume":"34","author":"Oldenburg","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"29","key":"10.1016\/j.bbrc.2025.152826_bib22","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1200\/JCO.2015.60.9347","article-title":"Management of nasopharyngeal carcinoma: current practice and future perspective","volume":"33","author":"Lee","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbrc.2025.152826_bib23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1365-2559.2002.01436.x","article-title":"Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region","volume":"41","author":"Putti","year":"2002","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.bbrc.2025.152826_bib24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00005537-200401000-00029","article-title":"Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx","volume":"114","author":"Leong","year":"2004","journal-title":"Laryngoscope"},{"issue":"15","key":"10.1016\/j.bbrc.2025.152826_bib25","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1200\/JCO.2005.02.147","article-title":"Multicenter, phase ii study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma","volume":"23","author":"Chan","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"18_suppl","key":"10.1016\/j.bbrc.2025.152826_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.15509","article-title":"Phase ii study of gefitinib in metastatic or locoregionally recurrent nasopharyngeal carcinoma (npc)","volume":"24","author":"Chan","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2025.152826_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/1756-8722-6-46","article-title":"A phase ii study of sorafenib (bay 43-9006) in recurrent diffuse large b cell lymphoma: an eastern cooperative oncology group study (e1404)","volume":"6","author":"Greenwald","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2025.152826_bib28","doi-asserted-by":"crossref","first-page":"1110281","DOI":"10.3389\/fonc.2023.1110281","article-title":"The short-term efficacy and safety of induction chemotherapy combined with pd-1 inhibitor or anti-egfr in locoregionally advanced nasopharyn geal carcinoma","volume":"13","author":"Xiang","year":"2013","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152826_bib29","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2174\/1570180820666230417093528","article-title":"Emerging heterocyclic epidermal growth factor receptor inhibitors for the management of cancer: a chemical review","volume":"21","author":"Rupali","year":"2024","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.bbrc.2025.152826_bib30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40011-024-01605-4","article-title":"Conformational transitions in egfr protein tyrosine kinase domain and their modulation by mutants","volume":"95","author":"Shaikh","year":"2025","journal-title":"Proc. Natl. Acad. Sci. India B Biol. Sci."},{"key":"10.1016\/j.bbrc.2025.152826_bib31","doi-asserted-by":"crossref","unstructured":"M. Oliveira-Cunha, W.G. Newman, A.K. Siriwardena, Epidermal growth factor receptor in pancreatic cancer, Cancers 3(2) 1513-1526.https:\/\/doi.org\/10.3390\/cancers3021513.","DOI":"10.3390\/cancers3021513"},{"key":"10.1016\/j.bbrc.2025.152826_bib32","doi-asserted-by":"crossref","unstructured":"R. Du, X. Wang, H. Zhou, et al., The health-related quality of life of lung cancer patients with egfr-t, Support. Care Cancer : Off. J. Multinational Assoc Supportive Care Cancer 30(12) 9889-9899.https:\/\/doi.org\/10.1007\/s00520-022-07451-2.","DOI":"10.1007\/s00520-022-07451-2"},{"key":"10.1016\/j.bbrc.2025.152826_bib33","doi-asserted-by":"crossref","unstructured":"P.A. J\u00e4nne, J.A. Engelman, B.E. Johnson, Epidermal growth factor receptor mutations in non-small-cell lung canc er: implications for treatment and tumor biology, J. Clin. Oncol.: Off. J.Am Soc. Clin.Oncol. 23(14) 3227-3234.https:\/\/doi.org\/10.1200\/JCO.2005.09.985.","DOI":"10.1200\/JCO.2005.09.985"},{"key":"10.1016\/j.bbrc.2025.152826_bib34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bbrc.2023.04.080","article-title":"Neuroglobin inhibits pancreatic cancer proliferation and metastasis by targeting the gnai1\/egfr\/akt\/erk signaling axis","volume":"664","author":"Wu","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2025.152826_bib35","article-title":"Sstr2 positively associates with egfr and predicts poor prognosis in n asopharyngeal carcinoma","author":"Xu","year":"2023","journal-title":"J.Clin. Pathology. jcp"},{"key":"10.1016\/j.bbrc.2025.152826_bib36","doi-asserted-by":"crossref","unstructured":"C.-J. Tsai, R. Nussinov, Emerging allosteric mechanism of egfr activation in physiological and pathological contexts, Biophys. J. 117(1) 5-13.https:\/\/doi.org\/10.1016\/j.bpj.2019.05.021.","DOI":"10.1016\/j.bpj.2019.05.021"},{"key":"10.1016\/j.bbrc.2025.152826_bib37","doi-asserted-by":"crossref","unstructured":"D. Bojkova, S. Westhaus, R. Costa, et al., Sofosbuvir activates egfr-dependent pathways in hepatoma cells with im plications for liver-related pathological processes, Cells 9(4) 1003.https:\/\/doi.org\/10.3390\/cells9041003.","DOI":"10.3390\/cells9041003"},{"issue":"19","key":"10.1016\/j.bbrc.2025.152826_bib38","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/onc.2012.267","article-title":"Hyperactivation of constitutively dimerized oncogenic egf receptors by autocrine loops","volume":"32","author":"Laisney","year":"2013","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.bbrc.2025.152826_bib39","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/bcr1769","article-title":"Autocrine wnt signaling contributes to breast cancer cell proliferation via the canonical wnt pathway and egfr transactivation","volume":"9","author":"Schlange","year":"2007","journal-title":"Breast Cancer Res."},{"issue":"17","key":"10.1016\/j.bbrc.2025.152826_bib40","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.1158\/0008-5472.CAN-17-3858","article-title":"Upregulation of e3 ubiquitin ligase cblc enhances egfr dysregulation and signaling in lung adenocarcinoma","volume":"78","author":"Hong","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2025.152826_bib41","doi-asserted-by":"crossref","unstructured":"E.S. Taylor, L. Pol-Fachin, R.D. Lins, et al., Conformational stability of the epidermal growth factor (egf) receptor as influenced by glycosylation, dimerization and egf hormone binding, Proteins 85(4) 561-570.https:\/\/doi.org\/10.1002\/prot.25220.","DOI":"10.1002\/prot.25220"},{"issue":"33","key":"10.1016\/j.bbrc.2025.152826_bib42","doi-asserted-by":"crossref","first-page":"10611","DOI":"10.1021\/jacs.6b05602","article-title":"Conformational changes in the epidermal growth factor receptor: role of the transmembrane domain investigated by coarse-grained metadynamics free energy calculations","volume":"138","author":"Lelimousin","year":"2016","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152826_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10930-017-9696-z","article-title":"Phosphorylation: implications in cancer","volume":"36","author":"Singh","year":"2017","journal-title":"Protein J."},{"issue":"2","key":"10.1016\/j.bbrc.2025.152826_bib44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00432-021-03800-6","article-title":"Egfr transcriptionally upregulates utx via stat3 in non-small cell lung cancer","volume":"148","author":"Zhou","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152826_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cells13010047","article-title":"Targeted inhibitors of egfr: structure, biology, biomarkers, and clinical applications","volume":"13","author":"Shaban","year":"2023","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.bbrc.2025.152826_bib46","first-page":"629","article-title":"[effect evaluation of allergen specific immunotherapy in patients with allergic rhinitis and asthma","volume":"29","author":"Song","year":"2015","journal-title":"Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"issue":"11","key":"10.1016\/j.bbrc.2025.152826_bib47","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1021\/acs.molpharmaceut.8b00672","article-title":"Synthesis and characterization of cetuximab-docetaxel and panitumumab-docetaxel antibody-drug conjugates for egfr-overexpressing cancer therapy","volume":"15","author":"Glatt","year":"2018","journal-title":"Mol. Pharm."},{"issue":"35","key":"10.1016\/j.bbrc.2025.152826_bib48","doi-asserted-by":"crossref","first-page":"13401","DOI":"10.1074\/jbc.RA118.004139","article-title":"Allosteric regulation of epidermal growth factor (egf) receptor ligand binding by tyrosine kinase inhibitors","volume":"293","author":"Macdonald-Obermann","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152826_bib49","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1186\/s12885-024-13168-8","article-title":"Egfr-tkis or egfr-tkis combination treatments for untreated advanced egfr-mutated nsclc: a network meta-analysis","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Cancer"},{"issue":"15_suppl","key":"10.1016\/j.bbrc.2025.152826_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e20671","article-title":"Therapeutic efficacy comparison of six major egfr-tkis in non-small-cell lung cancer patients with an activating egfr mutation: a network meta-analysis","volume":"37","author":"Wu","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbrc.2025.152826_bib51","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1245\/s10434-006-9227-1","article-title":"Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments","volume":"14","author":"Steeghs","year":"2007","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.bbrc.2025.152826_bib52","doi-asserted-by":"crossref","unstructured":"U. Batra, B. Biswas, K. Prabhash, et al., Differential clinicopathological features, treatments and outcomes in patients with exon 19 deletion and exon 21 l858r egfr mutation-positiv e adenocarcinoma non-small-cell lung cancer, BMJ Open Respiratory Res. 10(1) e001492.https:\/\/doi.org\/10.1136\/bmjresp-2022-001492.","DOI":"10.1136\/bmjresp-2022-001492"},{"issue":"3","key":"10.1016\/j.bbrc.2025.152826_bib53","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10822-019-00270-4","article-title":"Dissecting the molecular recognition of dual lapatinib derivatives for egfr\/her2","volume":"34","author":"Bello","year":"2020","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.bbrc.2025.152826_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0025-7753(16)30257-3","article-title":"Mecanismo de acci\u00f3n y desarrollo precl\u00ednico de afatinib","volume":"146","author":"Diz Ta\u00edn","year":"2016","journal-title":"Med. Cl\u00ednica"},{"issue":"2","key":"10.1016\/j.bbrc.2025.152826_bib55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.bbrc.2025.152826_bib56","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s40265-017-0811-4","article-title":"Neratinib: first global approval","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2025.152826_bib57","author":"Zhang"},{"issue":"10","key":"10.1016\/j.bbrc.2025.152826_bib58","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40265-017-0776-3","article-title":"Brigatinib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.bbrc.2025.152826_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084250","article-title":"Apoferritin\/vandetanib association is long-term stable but does not improve pharmacological properties of vandetanib","volume":"22","author":"J\u00e1klov\u00e1","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.bbrc.2025.152826_bib60","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s40265-018-0997-0","article-title":"Pyrotinib: first global approval","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2025.152826_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107088","article-title":"Lipocalin 2 (lcn2) confers acquired resistance to almonertinib in nsclc through lcn2-mmp-9 signaling pathway","volume":"201","author":"Shi","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.bbrc.2025.152826_bib62","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40265-016-0606-z","article-title":"Olmutinib: first global approval","volume":"76","author":"Kim","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2025.152826_bib63","unstructured":"W. Hu, W. Wang, P. Yang, et al., Phase i study of icotinib, an egfr tyrosine kinase inhibitor combined with imrt in nasopharyngeal carcinoma, Int. J. Clin. Exp. Med. 8(9) 15675-15683."},{"key":"10.1016\/j.bbrc.2025.152826_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2023.106115","article-title":"Community detection in epstein-barr virus associated carcinomas and role of tyrosine kinase in etiological mechanisms for oncogenesis","volume":"180","author":"Chatterjee","year":"2023","journal-title":"Microb. Pathog."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152826_bib65","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1038\/s41598-021-84171-3","article-title":"Anti-egfr antibody 528 binds to domain iii of egfr at a site shifted from the cetuximab epitope","volume":"11","author":"Makabe","year":"2021","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.bbrc.2025.152826_bib66","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/bph.12047","article-title":"Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients","volume":"168","author":"Xie","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.bbrc.2025.152826_bib67","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1517\/14656566.5.7.1621","article-title":"Cetuximab: an igg(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours","volume":"5","author":"Humblet","year":"2004","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.bbrc.2025.152826_bib68","article-title":"Nimotuzumab, an anti-egfr monoclonal antibody, in the treatment of nasopharyngeal carcinoma, cancer control","volume":"28","author":"Liang","year":"2021","journal-title":"J. Moffitt Cancer Center"},{"key":"10.1016\/j.bbrc.2025.152826_bib69","doi-asserted-by":"crossref","unstructured":"D. Hoda, G.R. Simon, C.R. Garrett, Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab, Therapeut. Clin. Risk Manag. 4(6) 1221-1227.https:\/\/doi.org\/10.2147\/tcrm.s4314.","DOI":"10.2147\/TCRM.S4314"},{"key":"10.1016\/j.bbrc.2025.152826_bib70","doi-asserted-by":"crossref","unstructured":"M. Miroddi, C. Sterrantino, M. Simmonds, et al., Systematic review and meta-analysis of the risk of severe and life-thr eatening thromboembolism in cancer patients receiving anti-egfr monocl onal antibodies (cetuximab or panitumumab), Int. J. Cancer 139(10) 2370-2380.https:\/\/doi.org\/10.1002\/ijc.30280.","DOI":"10.1002\/ijc.30280"},{"issue":"4","key":"10.1016\/j.bbrc.2025.152826_bib71","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.bbrc.2025.152826_bib72","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.7150\/thno.19710","article-title":"Concurrent chemoradiotherapy with or without anti-egfr-targeted treatment for stage ii-ivb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up","volume":"7","author":"You","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.bbrc.2025.152826_bib73","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.oraloncology.2017.02.026","article-title":"Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: a propensity score analysis","volume":"67","author":"Xia","year":"2017","journal-title":"Oral Oncol."},{"issue":"10","key":"10.1016\/j.bbrc.2025.152826_bib74","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1017\/S0022215119001853","article-title":"Cetuximab in the management of nasopharyngeal carcinoma \u2013 a narrative review","volume":"133","author":"Iqbal","year":"2019","journal-title":"J. Laryngol. Otol."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152826_bib75","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1186\/s12885-017-3552-6","article-title":"Concurrent chemoradiotherapy with or without cetuximab for stage ii to ivb nasopharyngeal carcinoma: a case-control study","volume":"17","author":"Li","year":"2017","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.bbrc.2025.152826_bib76","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.oraloncology.2015.06.008","article-title":"Weekly cetuximab concurrent with imrt aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: results of a randomized phase ii study","volume":"51","author":"Xu","year":"2015","journal-title":"Oral Oncol."},{"key":"10.1016\/j.bbrc.2025.152826_bib77","article-title":"Nimotuzumab, an anti-egfr monoclonal antibody","volume":"28","author":"Liang","year":"2021","journal-title":"Treatment Nasopharyngeal Carcinoma"},{"issue":"5","key":"10.1016\/j.bbrc.2025.152826_bib78","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.21873\/invivo.13323","article-title":"Cetuximab plus concurrent radiotherapy in patients with nasopharyngeal carcinoma","volume":"37","author":"Yamauchi","year":"2023","journal-title":"In Vivo"},{"issue":"42","key":"10.1016\/j.bbrc.2025.152826_bib79","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017486","article-title":"A meta-analysis of cisplatin-based concurrent chemoradiotherapy with or without cetuximab for locoregionally advanced nasopharyngeal carcinoma","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine"},{"issue":"15_suppl","key":"10.1016\/j.bbrc.2025.152826_bib80","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.e17035","article-title":"Cetuximab plus cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma","volume":"32","author":"Kerboua","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152826_bib81","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.5114\/aoms.2019.86712","article-title":"Induction chemotherapy plus nimotuzumab followed by concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma","volume":"17","author":"Song","year":"2021","journal-title":"Arch. Med. Sci."},{"issue":"12","key":"10.1016\/j.bbrc.2025.152826_bib82","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1080\/15384047.2018.1491501","article-title":"Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma","volume":"19","author":"Yao","year":"2018","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152826_bib83","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1186\/s12885-019-6156-5","article-title":"The long-term survival of patients with iii-ivb stage nasopharyngeal carcinoma treated with imrt with or without nimotuzumab: a propensity score-matched analysis","volume":"19","author":"Zhi-Qiang","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.bbrc.2025.152826_bib84","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/annonc\/mdz020","article-title":"Anti-epidermal growth factor receptor (egfr) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase ii clinical trial","volume":"30","author":"Zhao","year":"2019","journal-title":"Ann. Oncol. : Off. J. European Soc.Med. Oncol."},{"issue":"4","key":"10.1016\/j.bbrc.2025.152826_bib85","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000488087","article-title":"Anti-angiogenics: current situation and future perspectives","volume":"41","author":"Zirlik","year":"2018","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.bbrc.2025.152826_bib86","doi-asserted-by":"crossref","unstructured":"Y.-J. Kim, M. Oremus, H.H. Chen, et al., Cost-effectiveness analysis of afatinib, erlotinib, and gefitinib as f irst-line treatments for egfr mutation-positive non-small-cell lung ca ncer in ontario, Canada, Pharmacoeconomics 39(5) 537-548.https:\/\/doi.org\/10.1007\/s40273-021-01022-9.","DOI":"10.1007\/s40273-021-01022-9"},{"issue":"5","key":"10.1016\/j.bbrc.2025.152826_bib87","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/1078-0432.CCR-17-1667","article-title":"Efficacy, safety, and pharmacokinetics of axitinib in nasopharyngeal carcinoma: a preclinical and phase ii correlative study","volume":"24","author":"Hui","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152826_bib88","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1186\/s12916-023-02790-1","article-title":"The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and\/or recurrent nasopharyngeal carcinoma: a prospective, phase ii trial","volume":"21","author":"Tang","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.bbrc.2025.152826_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105222","article-title":"Efficacy and safety of apatinib in recurrent\/metastatic nasopharyngeal carcinoma: a pilot study","volume":"115","author":"Huang","year":"2021","journal-title":"Oral Oncol."},{"issue":"17","key":"10.1016\/j.bbrc.2025.152826_bib90","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1002\/cncr.33626","article-title":"Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: a multicenter, single-arm, prospective phase 2 study","volume":"127","author":"Ruan","year":"2021","journal-title":"Cancer"},{"issue":"43","key":"10.1016\/j.bbrc.2025.152826_bib91","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proceed. National Academy Sci. United States America"},{"key":"10.1016\/j.bbrc.2025.152826_bib92","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2147\/DDDT.S244102","article-title":"Safety and feasibility of low-dose apatinib combined with s-1 as the second-line therapy or beyond in Chinese patients with pulmonary and hepatic metastasis of nasopharyngeal carcinoma","volume":"14","author":"Zhou","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.bbrc.2025.152826_bib93","doi-asserted-by":"crossref","unstructured":"M.E. Delgado, M. Olsson, F.A. Lincoln, et al., Determining the contributions of caspase-2, caspase-8 and effector cas pases to intracellular vdvadase activities during apoptosis initiation and execution, Biochim. Biophys. Acta 1833(10) 2279-2292.https:\/\/doi.org\/10.1016\/j.bbamcr.2013.05.025.","DOI":"10.1016\/j.bbamcr.2013.05.025"},{"issue":"1","key":"10.1016\/j.bbrc.2025.152826_bib94","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01928-2","article-title":"Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbrc.2025.152826_bib95","doi-asserted-by":"crossref","unstructured":"T. Yamaoka, M. Ohba, T. Ohmori, Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms, Int. J. Mol. Sci. 18(11) 2420.https:\/\/doi.org\/10.3390\/ijms18112420.","DOI":"10.3390\/ijms18112420"},{"key":"10.1016\/j.bbrc.2025.152826_bib96","doi-asserted-by":"crossref","unstructured":"Y. Cui, J. Shi, Y. Cui, et al., The relationship between autophagy and pd-l1 and their role in antitumor therapy, 142023 https:\/\/doi.org\/10.3389\/fimmu.2023.1093558.","DOI":"10.3389\/fimmu.2023.1093558"},{"issue":"11","key":"10.1016\/j.bbrc.2025.152826_bib97","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/stem.2703","article-title":"Genetic evolution of glioblastoma stem-like cells from primary to recurrent tumor","volume":"35","author":"Orzan","year":"2017","journal-title":"Stem Cell."},{"issue":"7868","key":"10.1016\/j.bbrc.2025.152826_bib98","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-021-03648-3","article-title":"Clonal fitness inferred from time-series modelling of single-cell cancer genomes","volume":"595","author":"Salehi","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2025.152826_bib99","first-page":"213","volume":"vol. 2","author":"Spranger","year":"2018"},{"key":"10.1016\/j.bbrc.2025.152826_bib100","author":"Wu"},{"issue":"3","key":"10.1016\/j.bbrc.2025.152826_bib101","first-page":"185","article-title":"Maackiain inhibits proliferation and promotes apoptosis of nasopharyngeal carcinoma cells by inhibiting the mapk\/ras signaling pathway","volume":"21","author":"Xing","year":"2023","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.bbrc.2025.152826_bib102","doi-asserted-by":"crossref","unstructured":"L.-X. Peng, M.-D. Wang, P. Xie, et al., Lactb promotes metastasis of nasopharyngeal carcinoma via activation o f erbb3\/egfr-erk signaling resulting in unfavorable patient survival, Cancer Lett. 498165-498177.https:\/\/doi.org\/10.1016\/j.canlet.2020.10.051.","DOI":"10.1016\/j.canlet.2020.10.051"},{"key":"10.1016\/j.bbrc.2025.152826_bib103","doi-asserted-by":"crossref","unstructured":"Z. Zhou, W. Wang, X. Xie, et al., Methylation-induced silencing of spg20 facilitates gastric cancer cell proliferation by activating the egfr\/mapk pathway, Biochem. Biophys. Res. Commun. 500(2) 411-417.https:\/\/doi.org\/10.1016\/j.bbrc.2018.04.089.","DOI":"10.1016\/j.bbrc.2018.04.089"},{"issue":"21","key":"10.1016\/j.bbrc.2025.152826_bib104","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.1158\/1078-0432.CCR-15-2996","article-title":"Loss of arid1a activates anxa1, which serves as a predictive biomarker for trastuzumab resistance","volume":"22","author":"Berns","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2025.152826_bib105","doi-asserted-by":"crossref","unstructured":"Y. Wang, L. Serfass, M.O. Roy, et al., Annexin-i expression modulates drug resistance in tumor cells, Biochem. Biophys. Res. Commun. 314(2) 565-570.https:\/\/doi.org\/10.1016\/j.bbrc.2003.12.117.","DOI":"10.1016\/j.bbrc.2003.12.117"},{"key":"10.1016\/j.bbrc.2025.152826_bib106","doi-asserted-by":"crossref","unstructured":"J.-H. Lee, H.-H. Lee, K.D. Ryu, et al., Kcp10043f represses the proliferation of human non-small cell lung can cer cells by caspase-mediated apoptosis via stat3 inactivation, J. Clin. Med. 9(3) 704.https:\/\/doi.org\/10.3390\/jcm9030704.","DOI":"10.3390\/jcm9030704"},{"key":"10.1016\/j.bbrc.2025.152826_bib107","doi-asserted-by":"crossref","unstructured":"A. Fendri, A. Khabir, W. Mnejja, et al., Pik3ca amplification is predictive of poor prognosis in tunisian patie nts with nasopharyngeal carcinoma, Cancer Sci. 100(11) 2034-2039.https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01292.x.","DOI":"10.1111\/j.1349-7006.2009.01292.x"},{"key":"10.1016\/j.bbrc.2025.152826_bib108","doi-asserted-by":"crossref","unstructured":"S. Kobayashi, T.J. Boggon, T. Dayaram, et al., Egfr mutation and resistance of non-small-cell lung cancer to gefitini b, N. Engl. J. Med. 352(8) 786-792.https:\/\/doi.org\/10.1056\/NEJMoa044238.","DOI":"10.1056\/NEJMoa044238"},{"key":"10.1016\/j.bbrc.2025.152826_bib109","doi-asserted-by":"crossref","unstructured":"K. Sakai, A. Horiike, D.L. Irwin, et al., Detection of epidermal growth factor receptor t790m mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyro sine kinase inhibitor, Cancer Sci. 104(9) 1198-1204.https:\/\/doi.org\/10.1111\/cas.12211.","DOI":"10.1111\/cas.12211"},{"key":"10.1016\/j.bbrc.2025.152826_bib110","author":"Poh"},{"issue":"3","key":"10.1016\/j.bbrc.2025.152826_bib111","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/prot.26761","article-title":"L858r\/l718q and l858r\/l792h mutations of egfr inducing resistance against osimertinib by forming additional hydrogen bonds","volume":"93","author":"Imam","year":"2025","journal-title":"Proteins"},{"key":"10.1016\/j.bbrc.2025.152826_bib112","article-title":"Overcoming c797s mutation: the challenges and prospects of the fourth-generation egfr-tkis","volume":"128","author":"Hong-Yi","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbrc.2025.152826_bib113","article-title":"Fighting tertiary mutations in egfr-driven lung-cancers: current advances and future perspectives in medicinal chemistry","volume":"190","author":"Laura","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152826_bib114","doi-asserted-by":"crossref","first-page":"109887","DOI":"10.1016\/j.cellsig.2020.109887","article-title":"The microrna cluster mir-214\/mir-3120 prevents tumor cell switching fr om an epithelial to a mesenchymal-like phenotype and inhibits autophag y in gallbladder cancer","volume":"80","author":"Li","year":"2021","journal-title":"Cell. Signal."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152826_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/cells12030416","article-title":"The role of cytokines in epithelial-mesenchymal transition in gynaecological cancers: a systematic review","volume":"12","author":"Ray","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bbrc.2025.152826_bib116","doi-asserted-by":"crossref","unstructured":"M.A. Huber, N. Kraut, H. Beug, Molecular requirements for epithelial-mesenchymal transition during tu mor progression, Curr. Opin. Cell Biol. 17(5) 548-558.https:\/\/doi.org\/10.1016\/j.ceb.2005.08.001.","DOI":"10.1016\/j.ceb.2005.08.001"},{"key":"10.1016\/j.bbrc.2025.152826_bib117","doi-asserted-by":"crossref","unstructured":"Y. Yu, L. Ke, X. Lv, et al., The prognostic significance of carcinoma-associated fibroblasts and tu mor-associated macrophages in nasopharyngeal carcinoma, Cancer Manag. Res. 10 1935-1946.https:\/\/doi.org\/10.2147\/CMAR.S167071.","DOI":"10.2147\/CMAR.S167071"},{"key":"10.1016\/j.bbrc.2025.152826_bib118","volume":"vol. 12","author":"Zhao","year":"2022"},{"key":"10.1016\/j.bbrc.2025.152826_bib119","author":"Yin"},{"issue":"12","key":"10.1016\/j.bbrc.2025.152826_bib120","first-page":"3422","article-title":"Blocking leptin-stat3 axis-induced fatty acid oxidation: a novel approach to activate cd8+ t effector cells in breast","volume":"11","author":"Ruan","year":"2020","journal-title":"cancer"},{"key":"10.1016\/j.bbrc.2025.152826_bib121","author":"Wen"},{"issue":"3","key":"10.1016\/j.bbrc.2025.152826_bib122","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-020-05819-8","article-title":"Evaluation of pd-l1, tumor-infiltrating lymphocytes, and cd8+ and foxp3+ immune cells in her2-positive breast cancer treated with neoadjuvant therapies","volume":"183","author":"Zhao","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"issue":"8","key":"10.1016\/j.bbrc.2025.152826_bib123","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1158\/1078-0432.CCR-19-2027","article-title":"Impact of egfr-tki treatment on the tumor immune microenvironment in egfr mutation-positive non-small cell lung cancer","volume":"26","author":"Isomoto","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2025.152826_bib124","volume":"vol. 12","author":"Zheng","year":"2021"},{"key":"10.1016\/j.bbrc.2025.152826_bib125","doi-asserted-by":"crossref","unstructured":"M. Benadiba, Y. Maor, Importance of abc transporters in drug development, Curr. Pharm. Des. 22(38) 5817-5829.https:\/\/doi.org\/10.2174\/1381612822666160810120359.","DOI":"10.2174\/1381612822666160810120359"},{"key":"10.1016\/j.bbrc.2025.152826_bib126","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2021.02.019","article-title":"Osimertinib versus osimertinib plus chemotherapy for non\u2013small cell lung cancer with egfr (t790m)-associated resistance to initial egfr inhibitor treatment: an open-label, randomised phase 2 clinical trial","volume":"149","author":"Kentaro","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbrc.2025.152826_bib127","doi-asserted-by":"crossref","unstructured":"A. Martinez-Marti, E. Felip, J. Matito, et al., Dual met and erbb inhibition overcomes intratumor plasticity in osimer tinib-resistant-advanced non-small-cell lung cancer (nsclc), Ann. Oncol. : Off. J. European Soc.Med. Oncol. 28(10) 2451-2457.https:\/\/doi.org\/10.1093\/annonc\/mdx396.","DOI":"10.1093\/annonc\/mdx396"},{"issue":"6","key":"10.1016\/j.bbrc.2025.152826_bib128","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1021\/acs.chemrev.1c00118","article-title":"Introduction: drug resistance","volume":"121","author":"Kurt Yilmaz","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bbrc.2025.152826_bib129","author":"Wu"},{"issue":"12","key":"10.1016\/j.bbrc.2025.152826_bib130","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1007\/s00432-021-03828-8","article-title":"Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored egfr mutation: from mechanism analysis to clinical strategy","volume":"147","author":"Zhao","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25015426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25015426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:15:46Z","timestamp":1777389346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25015426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":130,"alternative-id":["S0006291X25015426"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152826","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applications and challenges of EGFR inhibitors in the treatment of nasopharyngeal carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152826"}}